Key Points
- Zhonghui Medical Technology Co., Ltd, or Sinoways, is a focused ultrasound company based in Shanghai, China.
- The company is developing and testing a focused ultrasound device for the noninvasive treatment of uterine fibroids.
- This profile is available in both simplified and traditional Chinese.
Zhonghui Medical Technology Co., Ltd, or Sinoways, is based in Shanghai, China, and is developing and testing a focused ultrasound device for the noninvasive treatment of uterine fibroids.
We recently spoke with the company’s Vice General Manager, Dong Zhe-hua, about the company’s origins, its innovative device, and how their clinical studies are improving women’s health.
中惠医疗科技有限公司总部位于中国上海，正在开发和测试一种用于子宫肌瘤无创治疗的聚焦超声设备。
我们最近采访了该公司的副总经理董喆华，了解该公司的起源、其创新的设备以及他们的临床研究如何改善女性健康。
How was the company started?
贵公司是如何开始的？
Zhonghui Medical Technology Co., Ltd. was incorporated in Shanghai in January 2015 and focuses on the development of noninvasive focused ultrasound equipment and services. At its start, the company worked closely with Shanghai Jiaotong University as part of an industry-university research cooperation, and the relationship remains today.
中惠医疗科技有限公司于2015年1月在上海注册成立，专注于无创聚焦超声设备及服务的研发。成立之初，作为产学研合作的一部分，公司与上海交通大学密切合作，这种关系一直延续至今。
How did you get involved in starting or joining the company?
您是如何参与创办或加入公司的？
I joined Sinoways in 2018 as Vice General Manager. Before that, I worked in sales and marketing in the medical equipment industry for more than 10 years.
我于 2018 年加入 Sinoways，担任副总经理。在此之前，我在医疗设备行业从事销售和营销工作超过 10 年。
Tell us about your company structure: ownership, lead executives, and their roles.
告诉我们贵公司的结构：股权结构，高管人员及其角色
The company has established a scientific research, engineering transformation, and marketing team of more than 40 people with rich experience in large-scale medical devices across Shanghai and Yangzhou. The main research center is in Shanghai. Ninety percent of our personnel have backgrounds in the field of medical devices.
Mr. Xiaoping Ju is the biggest shareholder and an experienced investor and expert in medical instruments.
Ms. Yazhu Chen is an academician from the Chinese Academy of Engineering. She and her team provide technical assurance.
We are also actively hiring for a number of engineering positions. Visit our website to learn more.
公司在上海和扬州拥有一支40余人的团队。我们在科研、工程、营销团队，和大型医疗器械方面具有丰富的经验。主要的人员都位于上海，我们百分之九十的人员具有医疗器械领域的背景。
居小平先生为第一大股东，他在医疗器械领域是一位经验丰富的投资人和专家。
陈亚珠女士，中国工程院院士。她和她的团队提供技术保证。
我们仍在积极招聘多个工程师职位。请参照我们的网站以了解更多信息。
How many years has your treatment platform been in development, and what are its origins? Does it have a name?
贵公司的治疗平台已经开发了多少年，其起源是什么？该机器或疗程有名称吗？
Our treatment platform, SUA-I PHIFU system, has been in development for approximately seven years. The first prototype was developed in 2015. In 2017, we secured a patent for the device and were able to officially begin work related to clinical trials. The next year, we completed preclinical studies and safely conducted our first clinical trial.
我们的治疗平台 SUA-I PHIFU 系统已经开发了大约七年。第一台样机于2015年开发完成，2017年我们获得了该设备的专利，并得以正式开展临床试验相关工作。隔年，我们完成了临床前研究并安全地进行了我们的第一次的临床试验。
What are some of the technical challenges your group has to overcome to develop a fully noninvasive system?
贵公司的团队要开发一个完全无创的系统必须克服哪些技术挑战？
The technical challenges we’ve encountered are three-fold:
- Image guidance using real-time intraoperative ultrasound with different modes like MRI and CT
- Treatment plan position control to ensure the procedure is safe, smooth, quick, and precise
- Image quality control, especially accounting for the different depths of treatment focus that are required.
我们遇到的技术挑战有三方面：
1. 使用不同模式的影像导引技术如核磁共振(MRI) 和电脑断层 (CT)以在术中即时进行超声影像导引
2. 治疗方案定位控制，确保手术过程安全、顺畅、快速、精准
3. 图像质量控制，特别是考虑到不同治疗焦点所需的深度。
What challenges do you have to tackle moving forward?
贵公司接下来必需面对哪些挑战？
We are developing a clinical indications plan and will need to conduct more research.
我们正在制定临床适应症的计划，需要进行更多研究。
Tell us about your clinical studies and the results.
请告诉我们贵公司的临床研究和结果。
We have partnered with the International Peace Maternity & Child Health Hospital of China Welfare Institute (IPMCH), the First Affiliated Hospital of Soochow University, and Jiangxi Provincial People’s Hospital. We have completed approximately 120 treatments for patients with uterine fibroids, and all went well.
我们与中国福利会国际和平妇幼保健院（IPMCH）、苏州大学第一附属医院、江西省人民医院建立了合作关系。我们已经完成了大约120例子宫肌瘤患者的治疗，一切都很顺利。
What are the benefits of your technology over other companies?
与其他公司相比，贵公司的技术有什么好处？
Our SUA-I PHIFU system is energy efficient and can evenly control temperature rise in the targeted area. Our system also features a phased array feature that enables precision position control. We also planned and developed our platform with a modular design, which helps control the cost and brings more value to customers.
我们的 SUA-I PHIFU 系统高效节能，可以均匀控制目标区域的温升。我们的系统还具有相控阵功能，可实现精确的位置控制。我们还以模块化设计规划和开发我们的平台，这有助于控制成本并为客户带来更多价值。
Have you learned any lessons for watching the experience of the other companies?
贵公司藉由观察其他公司而取的经验教训？
There are two important takeaways that we have gleaned from others in the field. We maintain close cooperation with top institutions for different clinical indications, and we learned valuable lessons related to product direction. We sought to create a portable, cost-effective product with excellent performance.
我们从该领域的其他人那里收集到了两个重要的收获。我们与顶级机构针对不同的临床适应症保持密切合作，并从中吸取了与产品方向相关的宝贵经验。我们力求打造一款性能卓越、高机动性和高性价比的产品。
Do you partner with other organizations?
贵公司是否与其他公司合作？
Yes, we partner with other organizations. We work with Shanghai JiaoTong University to develop our device.
We also have a network of world-class accessories suppliers, including those in the United States, Switzerland, and Japan.
是的，我们有与其他组织机构合作。中惠与上海交通大学合作开发设备。我们还拥有世界一流的配件供应商网络，包括美国、瑞士和日本的供应商。
Is your system approved for commercial use in any markets? If so, how is it being used in these markets?
贵公司的系统是否已获准在任何市场（国家）上用于商业用途？如果是这样，它在这些市场中如何被应用？
Not yet. We anticipate that the China Food and Drug Administration (CFDA) will approve our device to treat uterine fibroids in 2023.
还没有。但我们预计中国食品药品监督管理局 (CFDA) 将在 2023 年批准我们用于治疗子宫肌瘤的设备。
Which health conditions or diseases will your technology be used for?
贵公司的技术可用于治疗哪些健康状况或疾病？
Thus far, we are focusing on uterine fibroids, but we are evaluating other indications.
We are also interested in veterinary applications. We have developed the first generation of a focused ultrasound device for pet tumors, and two animal hospitals are beginning clinical treatments.
到目前为止，我们专注于子宫肌瘤，但我们正在评估其他适应症。
我们也对兽医应用感兴趣。我们已经研发出第一代宠物肿瘤聚焦超声设备并在两家动物医院开展临床治疗。
Traditional Chinese Translation
Company Profile: Sinoways 中惠醫療科技（上海）有限公司
Zhonghui Medical Technology Co., Ltd, or Sinoways, is based in Shanghai, China, and is developing and testing a focused ultrasound device for the noninvasive treatment of uterine fibroids.
We recently spoke with the company’s Vice General Manager, Dong Zhe-hua, about the company’s origins, its innovative device, and how their clinical studies are improving women’s health.
中惠醫療科技有限公司總部位於中國上海，正在開發和測試一種用於子宮肌瘤無創治療的聚焦超聲設備。
我們最近採訪了該公司的副總經理董喆華，瞭解該公司的起源、其創新的設備以及他們的臨床研究如何改善女性健康。
How was the company started?
貴公司是如何開始的？
Zhonghui Medical Technology Co., Ltd. was incorporated in Shanghai in January 2015 and focuses on the development of noninvasive focused ultrasound equipment and services. At its start, the company worked closely with Shanghai Jiaotong University as part of an industry-university research cooperation, and the relationship remains today.
中惠醫療科技有限公司於2015年1月在上海註冊成立，專注於無創聚焦超聲設備及服務的研發。成立之初，作為產學研合作的一部分，公司與上海交通大學密切合作，這種關係一直延續至今。
How did you get involved in starting or joining the company?
您是如何參與創辦或加入公司的？
I joined Sinoways in 2018 as Vice General Manager. Before that, I worked in sales and marketing in the medical equipment industry for more than 10 years.
我於 2018 年加入 Sinoways，擔任副總經理。在此之前，我在醫療設備行業從事銷售和營銷工作超過 10 年。
Tell us about your company structure: ownership, lead executives, and their roles.
告訴我們貴公司的結構：股權結構，高管人員及其角色
The company has established a scientific research, engineering transformation, and marketing team of more than 40 people with rich experience in large-scale medical devices across Shanghai and Yangzhou. The main research center is in Shanghai. Ninety percent of our personnel have backgrounds in the field of medical devices.
Mr. Xiaoping Ju is the biggest shareholder and an experienced investor and expert in medical instruments.
Ms. Yazhu Chen is an academician from the Chinese Academy of Engineering. She and her team provide technical assurance.
We are also actively hiring for a number of engineering positions. Visit our website to learn more.
公司在上海和揚州擁有一支40余人的團隊。我們在科研、工程、營銷團隊，和大型醫療器械方面具有豐富的經驗。主要的人員都位於上海，我們百分之九十的人員具有醫療器械領域的背景
居小平先生為第一大股東，他在醫療器械領域是一位經驗豐富的投資人和專家。
陳亞珠女士，中國工程院院士。她和她的團隊提供技術保證。
我們仍在積極招聘多個工程師職位。請參照我們的網站以瞭解更多信息。
How many years has your treatment platform been in development, and what are its origins? Does it have a name?
貴公司的治療平台已經開發了多少年，其起源是什麼？該機器或療程有名稱嗎？
Our treatment platform, SUA-I PHIFU system, has been in development for approximately seven years. The first prototype was developed in 2015. In 2017, we secured a patent for the device and were able to officially begin work related to clinical trials. The next year, we completed preclinical studies and safely conducted our first clinical trial.
我們的治療平台 SUA-I PHIFU 系統已經開發了大約七年。第一台樣機於2015年開發完成，2017年我們獲得了該設備的專利，並得以正式開展臨床試驗相關工作。隔年，我們完成了臨床前研究並安全地進行了我們的第一次的臨床試驗。
What are some of the technical challenges your group has to overcome to develop a fully noninvasive system?
貴公司的團隊要開發一個完全無創的系統必須克服哪些技術挑戰？
The technical challenges we’ve encountered are three-fold:
- Image guidance using real-time intraoperative ultrasound with different modes like MRI and CT
- Treatment plan position control to ensure the procedure is safe, smooth, quick, and precise
- Image quality control, especially accounting for the different depths of treatment focus that are required.
我們遇到的技術挑戰有三方面：
1. 使用不同模式的影像導引技術如核磁共振(MRI) 和電腦斷層 (CT)以在術中即時進行超聲影像導引
2. 治療方案定位控制，確保手術過程安全、順暢、快速、精准
3. 圖像質量控制，特別是考慮到不同治療焦點所需的深度。
What challenges do you have to tackle moving forward?
貴公司接下來必需面對哪些挑戰？
We are developing a clinical indications plan and will need to conduct more research.
我們正在制定臨床適應症的計劃，需要進行更多研究。
Tell us about your clinical studies and the results.
請告訴我們貴公司的臨床研究和結果。
We have partnered with the International Peace Maternity & Child Health Hospital of China Welfare Institute (IPMCH), the First Affiliated Hospital of Soochow University, and Jiangxi Provincial People’s Hospital. We have completed approximately 120 treatments for patients with uterine fibroids, and all went well.
我们与中国福利会国际和平妇幼保健院（IPMCH）、苏州大学第一附属医院、江西省人民医院建立了合作关系。我们已经完成了大约120例子宫肌瘤患者的治疗，一切都很顺利。
What are the benefits of your technology over other companies?
與其他公司相比，貴公司的技術有什麼好處？
Our SUA-I PHIFU system is energy efficient and can evenly control temperature rise in the targeted area. Our system also features a phased array feature that enables precision position control. We also planned and developed our platform with a modular design, which helps control the cost and brings more value to customers.
我們的 SUA-I PHIFU 系統高效節能，可以均勻控制目標區域的溫升。我們的系統還具有相控陣功能，可實現精確的位置控制。我們還以模塊化設計規劃和開發我們的平台，這有助於控製成本並為客戶帶來更多價值。
Have you learned any lessons for watching the experience of the other companies?
貴公司藉由觀察其他公司而取的經驗教訓？
There are two important takeaways that we have gleaned from others in the field. We maintain close cooperation with top institutions for different clinical indications, and we learned valuable lessons related to product direction. We sought to create a portable, cost-effective product with excellent performance.
我們從該領域的其他人那裡收集到了兩個重要的收穫。我們與頂級機構針對不同的臨床適應症保持密切合作，並從中吸取了與產品方向相關的寶貴經驗。我們力求打造一款性能卓越、高機動性和高性價比的產品。
Do you partner with other organizations?
貴公司是否與其他公司合作？
Yes, we partner with other organizations. We work with Shanghai JiaoTong University to develop our device.
We also have a network of world-class accessories suppliers, including those in the United States, Switzerland, and Japan.
是的，我們有與其他組織機構合作。中惠與上海交通大學合作開發設備。我們還擁有世界一流的配件供應商網絡，包括美國、瑞士和日本的供應商。
Is your system approved for commercial use in any markets? If so, how is it being used in these markets?
貴公司的系統是否已獲准在任何市場（國家）上用於商業用途？如果是這樣，它在這些市場中如何被應用？
Not yet. We anticipate that the China Food and Drug Administration (CFDA) will approve our device to treat uterine fibroids in 2023.
還沒有。但我們預計中國食品藥品監督管理局 (CFDA) 將在 2023 年批准我們用於治療子宮肌瘤的設備。
Which health conditions or diseases will your technology be used for?
貴公司的技術可用於治療哪些健康狀況或疾病？
Thus far, we are focusing on uterine fibroids, but we are evaluating other indications.
We are also interested in veterinary applications. We have developed the first generation of a focused ultrasound device for pet tumors, and two animal hospitals are beginning clinical treatments.
到目前為止，我們專注於子宮肌瘤，但我們正在評估其他適應症。
我們也對獸醫應用感興趣。我們已經研發出第一代寵物腫瘤聚焦超聲設備並在兩家動物醫院開展臨床治療。